Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations

Blood

Volumn 106, Issue 12, 2005, Pages 3740-3746

  Döhner, Konstanze ^a   Schlenk, Richard F ^b   Habdank, Marianne ^b   Scholl, Claudia ^b   Rücker, Frank G ^b   Corbacioglu, Andrea ^b   Bullinger, Lars ^b   Fröhling, Stefan ^b   Döhner, Hartmut ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HLA ANTIGEN; IDARUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; MUTANT PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DUPLICATION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; WHOLE BODY RADIATION;

EID: 28444473100     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2164     Document Type: Article

References (47)

1. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179-198.
2. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subgroup. Cancer Res. 1998;58:4173-4179.
3. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
5. Schlenk RF, Benner A, Hartmann F, et al. Riskadapted postremission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521-1528.
6. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261.
7. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380.
8. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-633.
9. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
10. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
11. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
12. Van Waalwijk Van Doorn-Khosravani SB, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003;4:31-40.
13. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61:7233-7239.
14. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56:379-390.
15. Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood. 1999;93:632-642.
16. Olson MO, Wallace MO, Herrera AH, Marshall-Carlson L, Hunt RC. Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction. Biochemistry. 1986;25:484-491.
17. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999;8:905-912.
18. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4:529-533.
19. Brady SN, Yu Y, Maggi LB Jr, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol. 2004;24:9327-9338.
20. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/ B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103:127-140.
21. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1995;267:316-317.
22. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87:882-886.
23. Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 1996;12:265-275.
24. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17:2312-2325.
25. Falini B, Mecucci C, Tiacci E, et al, for the GIMEMAAcute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.
26. Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem. 2002;66:2239-2242.
27. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:620-625.
28. Schlenk RF, Döhner H. Risk adapted therapy of AML: the AMLSG ULM experience [abstract]. Ann Hematol. 2001;83(suppl 1):49.
29. Mitelman F. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
30. Fröhling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002;20:2480-2485.
31. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255-260.
32. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [erratum in: J Clin Oncol. 2004;22:576.]. J Clin Oncol. 2003;21:4642-4649.
33. Therneau TM, Grambusch PM. Modeling survival data: extending the Cox model. New York, NY: Springer Verlag; 2000.
34. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
35. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analsysis. New York, NY: Springer Verlag; 2001.
36. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: 2005; Vienna, Austria.
37. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. Prepublished on May 3, 2005, as DOI 10.1182/blood-2005-03-0899.
38. (Now available as Blood. 2005;106:1419-1422.)
39. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462-469.
40. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517-3523.
41. Grisendi S, Pandolfi PP. NPM mutations in acute myelogenous leukemia. N Engl J Med. 2005;352:291-292.
42. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000;275:24451-24457.
43. Chang JH, Lin JY, Wu MH, Yung BY. Evidence for the ability of nucleophosmin/B23 to bind ATP. Biochem J. 1998;329:539-544.
44. Umekawa H, Sato K, Takemura M, et al. The carboxyl terminal sequence of nucleolar protein B23.1 is important in its DNA polymerase alphastimulatory activity. J Biochem (Tokyo). 2001;130:199-205.
45. + AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. Prepublished on April 14, 2005, as DOI 10.1182/blood-2005- 02-0560.
46. (Now available as Blood. 2005;106:899-902.)
47. McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489-3497.